| Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. | |
| | |
MedLine Citation:
|
PMID: 16907931 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: We evaluated the antithrombotic effects of statins and angiotensin-converting enzyme inhibitor (ACEI) drugs in patients with coronary artery disease (CAD). METHODS AND RESULTS: Blood coagulation at the site of microvascular injury was assessed in 26 males with CAD before and after treatment with quinapril (10 mg day-1; n=13) or atorvastatin (40 mg day-1; n=13) for 4 weeks and an additional 4 weeks of combined therapy (quinapril+atorvastatin). Rates of prothrombin and factor V activation (FVa), fibrinogen (Fbg) cleavage and FVa inactivation showed that both quinapril and atorvastatin decreased the rates of: formation of thrombin B-chain (by 30.6%, P=0.007; and by 34.3%, P=0.003), formation of thrombin-antithrombin complexes (by 30.4%, P=0.0002; and by 40%, P=0.001), FV activation (by 19.1%, P=0.03; and by 21.8%, P=0.005) and Fbg depletion (by 29.2%, P=0.004; and by 32.7%, P=0.001). Atorvastatin alone accelerated FVa inactivation (P=0.005). A further 4 weeks of combined therapy enhanced most anticoagulant effects only when atorvastatin was added to quinapril. CONCLUSIONS: In CAD patients, atorvastatin and quinapril slowed blood clotting at the site of microvascular injury after 28 days of therapy. Addition of atorvastatin to quinapril, but not quinapril to the statin, enhanced the anticoagulant effects. Our findings might help explain the reduced risk of myocardial infarction or stroke in patients treated with statins and/or ACEIs and the lack of clinical benefits from ACEI added to prior statin therapy in patients at cardiovascular risk. |
| | |
Authors:
|
A Undas; K E Brummel-Ziedins; D P Potaczek; B Stobierska-Dzierzek; L Bryniarski; A Szczeklik; K G Mann |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2006-08-14 |
Journal Detail:
|
Title: Journal of thrombosis and haemostasis : JTH Volume: 4 ISSN: 1538-7933 ISO Abbreviation: J. Thromb. Haemost. Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-10-24 Completed Date: 2006-12-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101170508 Medline TA: J Thromb Haemost Country: England |
Other Details:
|
Languages: eng Pagination: 2397-404 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Jagellonian University School of Medicine, Krakow, Poland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiotensin-Converting Enzyme Inhibitors / administration & dosage* Anticholesteremic Agents / administration & dosage* Blood Coagulation / drug effects* Blood Coagulation Factors / analysis Coronary Artery Disease / blood, complications, drug therapy* Double-Blind Method Evaluation Studies as Topic Heptanoic Acids / administration & dosage* Humans Male Middle Aged Myocardial Infarction / blood, etiology, prevention & control Pyrroles / administration & dosage* Risk Factors Stroke / blood, etiology, prevention & control Tetrahydroisoquinolines / administration & dosage* Time Factors |
| Grant Support | |
ID/Acronym/Agency:
|
HL-46703/HL/NHLBI NIH HHS; T32 HL-07594/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticholesteremic Agents; 0/Blood Coagulation Factors; 0/Heptanoic Acids; 0/Pyrroles; 0/Tetrahydroisoquinolines; 110862-48-1/atorvastatin; 82586-55-8/quinapril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Increased susceptibility of cord blood B lymphocytes to undergo spontaneous apoptosis.
Next Document: Oxidative stress and apoptotic events during thermal stress in the symbiotic sea anemone, Anemonia v...